Veracyte (NASDAQ:VCYT) versus Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Financial Analysis

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Valuation & Earnings

This table compares Lakefront Biotherapeutics American Depositary Shares and Veracyte”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$990.57 million	1.90	$363.05 million	($1.41)	-20.21
Veracyte	$561.90 million	6.08	$66.35 million	$1.41	30.16

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Veracyte. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Veracyte	20.37%	9.26%	8.61%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Lakefront Biotherapeutics American Depositary Shares and Veracyte, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	7	1	1	2.33
Veracyte	1	2	6	2	2.82

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $30.67, indicating a potential upside of 7.64%. Veracyte has a consensus price target of $54.33, indicating a potential upside of 27.75%. Given Veracyte’s stronger consensus rating and higher probable upside, analysts clearly believe Veracyte is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Institutional and Insider Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 1.6% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500.

Summary

Veracyte beats Lakefront Biotherapeutics American Depositary Shares on 11 of the 15 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.